DLQ-01 (latanoprost)
DLQ-01 (latanoprost) is in Phase 1/2 for androgenetic alopecia, developed by DermaLiq Therapeutics.
Nothing new since Apr 2024
- Developed by
- DermaLiq Therapeutics
- Current phase
- Phase 1/2
- Mechanism
- Prostaglandin
- Indications
- Androgenetic alopecia
- Also known as
- DLQ01, latanoprost topical
- Last public activity
- April 2024
- Record confidence
- Medium
A combined safety and early-efficacy study.
Acts on prostaglandins, lipid messengers that can lengthen or shorten the hair growth cycle.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Development history
- Phase 1/2
First Phase 1/2 trial on record: NCT05636904 — Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men
Dermaliq Therapeutics, Inc. · n=120 · December 2022
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Safety and Efficacy Study of Topical DLQ01 in Androgenetic Alopecia — ClinicalTrials.gov
- Dermaliq announces positive topline results from the Phase 1b/2a trial of DLQ01 in androgenetic alopecia in men — Company release, July 2024
Related programmes
Other programmes in the register with the same mechanism: Prostaglandin.
Cite this page
Hair Pipeline, "DLQ-01 (latanoprost) — development record", hairpipeline.com/pipeline/dlq-01-latanoprost